Clinical Trial

Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy

Study acronym: PROMOTE
Completed
View on ClinicalTrials.gov →
Summary
This research trial studies gene expression in patients with prostate cancer that has spread to other places in the body receiving cytochrome P450 17 alpha hydroxylase/17,20 lyase (CYP-17) inhibition therapy. Studying samples of tissue, blood, and urine in the laboratory from patients receiving CYP-17 inhibition therapy may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer. It may also help doctors understand how well patients respond to treatment.
Protocol Amendment History 2 changes
critical Trial completed 2026-08-15
minor Completion moved earlier: 2026-12-15 -> 2023-04-03 2026-08-15
Trial Details
NCT Number NCT01953640
Lead Sponsor Mayo Clinic
Collaborators: National Cancer Institute (NCI)
Conditions Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Enrollment 92 participants
Start Date 2013-05-30
Primary Completion 2015-12-03 (estimated)
Study Completion 2023-04-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-14